In Colorado, Toyobo Co., Ltd. recently signed a joint research and development contract related to biomanufacturing with DMC Biotechnologies Inc. The two companies aim to develop and commercialize sustainable key chemical compounds to be used as raw materials for general-purpose plastics by applying synthetic biology technologies to microorganisms.
Toyobo has signed the development agreement with DMC, to which it directly provided investment funding in March 2022, with the aim of developing and commercializing sustainable and cost efficient chemical compounds. The two parties plan to optimize the growth and production stages of microorganisms by using DMC’s “Dynamic Metabolic ControlTM”, a genetic technology involving the control of metabolic pathways and a precision fermentation process enabling the delivery of scalable bioprocesses. By leveraging this technology, the companies aim to enhance the production efficiency of the target substances or essential chemical compounds.
Toyobo plans to utilize optimized microorganisms designed by DMC as well as its unique fermentation and production optimization technologies with the goal of mass-producing essential compounds for sale. Looking ahead, Toyobo will also explore using the essential compounds, derived from eco-friendly biomass, as raw materials for its films and other plastic products.
Tags: Colorado, DMC Biotechnologies, Toyobo
Category: Fuels
